Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Lantheus Holdings excels in Q2 with strong sales and strategic acquisitions

Lantheus Holdings delivered strong financial performance in Q2 2024, driven by PYLARIFY's robust sales and strategic acquisitions strengthening their pipeline.
Despite facing challenges such as regulatory uncertainties and market competition, Lantheus remains well-positioned for growth and market leadership.
With a focus on innovation, market leadership, and strategic acquisitions, Lantheus is poised to capitalize on opportunities in the radiopharmaceutical market and drive sustained growth.

Lantheus Holdings reports robust Q3 performance amidst market opportunities

Lantheus Holdings (LNTH) delivered a strong performance in Q3 2024, driven by key products and revenue growth.
The company faces challenges in navigating market uncertainties and maintaining growth momentum.
Opportunities lie in expanding market presence, capitalizing on reimbursement changes, and advancing Alzheimer's diagnostics.
Overall, Lantheus Holdings shows promise for future growth and innovation in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the piflufolastat F 18 (formerly known as 18F-DCFPyL) CONDOR pivotal trial will be presented at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

Apellis Pharma

BridgeBio Pharma Inc

Johnson & Johnson

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Lantheus Holdings (LNTH) Soars 16.8%: Is Further Upside Left in the Stock?

Investors are cheering FDA approval for the company's prostate cancer imaging agent.

Why Lantheus Stock Is Soaring Today

The FDA has approved Lantheus Holdings Inc's (NASDAQ: LNTH) Pylarify, a positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. Pylarify is an F 18-labeled prostate-specific membrane antigen (PSMA) imaging agent for diagnosing prostate cancer.

Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

The stock price of Lantheus Holdings Inc (NASDAQ: LNTH) increased by over 20% pre-market. This is why it happened.

LNTH Stock Price: Over 20% Increase Pre-Market Explanation

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging age

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company's Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2021 Results - Earnings Call Transcript

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share fell 86.11% over the past year to $0.05, which beat the estimate of ($0.01).

Lantheus Holdings: Q1 Earnings Insights

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its first quarter ended March 31, 2021. The Company's worldwide revenue for the first quarter of 2021 totaled $92.5 million, compared with $90.7 million for the first qu

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--EXINI Diagnostics AB, a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence (AI) solutions to Find, Fight and Follow serious medical conditions, announced today that it has received CE Mark clearance for aPROMISE in Europe. aPROMISE is artificial intelligence-based, deep learning-enabled, medical device sof

EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced a strategic collaboration with Allegheny Health Network (AHN), a western Pennsylvania healthcare delivery system headquartered in Pittsburgh, PA. Under the agreement, Lantheus' microbubbles

Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1‑678-509-7599 (international callers) and provide passcode 9275247. A live webcast will also be available in the Investors s

Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko. Both report directly to Lantheus' Chief Medical Officer, Istvan Molnar, MD. "At Lantheus, our ultimate goal is to use world-class science

Lantheus Expands R&D Leadership Team with Key New Hires

Micron Technology

Benchmark Electronics

Marvell Technology

TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Facebook & Micron

Wall Street's top analysts are backing buy-rated stocks like Facebook and Micron

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced that Michael P. Duffy, Senior Vice President, Law and Public Policy and General Counsel will retire from Lantheus on June 4, 2021 after more than 13 years with Lantheus. Mr. Duffy will be re

Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel

The stock price of Lantheus Holdings Inc (NASDAQ: LNTH) increased by 9.95% today. This is why it happened.

LNTH Stock Price Increased 9.95%: Why It Happened

Lantheus Holdings Inc (NASDAQ: LNTH) has acquired the exclusive worldwide rights to develop, manufacture and commercialize NTI-1309, a PET oncology imaging agent from Noria Therapeutics Inc. NTI-1309 targets fibroblast activation protein (FAP), a target with potential broad imaging applicability and targeting oncology implications.

Lantheus Buys Rights To Fibroblast Activation Protein Targeting Imaging Biomarker

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced today it has acquired the exclusive, worldwide rights to develop, manufacture and commercialize NTI-1309, an innovative PET oncology imaging agent from Noria Therapeutics, Inc. NTI-1309 targets fi

Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria

Lantheus Holdings (LNTH) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Lantheus Holdings (LNTH) Enters Overbought Territory

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that updated biochemical tumor marker data from its pivotal Phase 2 trial of AZEDRA® (iobenguane I 131) were presented at the Endocrine Society's 2021 Annual Meeting, ENDO 2021. Dr. Camilo J

Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced the publication of the results of both pivotal studies for PyL™, an investigational PET imaging agent that targets prostate-specific membrane antigen (PSMA). The OSPREY Phase 2/3 trial resul

Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q4 2020 Results - Earnings Call Transcript

News for Lantheus Holdings Stock (LNTH)